



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

Total Completed Clinical Trials In Research Department, BMCHRC Jaipur

S. No.	Completed clinical trials	Investigator
1.	Protocol#:21707 Protocol: A single-arm, open-label Phase 4 study of darolutamide in addition to standard androgen deprivation therapy for participants in Indian with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)	Dr. Aseem Kr Samar
2.	Study Title: A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Dr. Aseem Kr Samar
3.	A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone- sensitive prostate cancer (mHSPC)	Dr. Pawan Agarwal
4.	A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer	Dr. Pawan Agarwal
5.	Protocol #: PERT.21.001 Protocol Entitled: A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.	Dr. Tarachand Gupta
6.	Study Title “A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients with Mesenchymal-Epithelial Transition (MET) exon 14 Skipping Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)” (Capmatinib)	Dr. Deepak Gupta
7.	Study Code: : CBYL719CIN02 Protocol Title: SPEAR(Study of PIK3CA mutations and Effectiveness and tolerability outcomes of Alpelisib in Real-world) A descriptive study of PIK3CA mutations and outcomes with Alpelisib in patients with HR-positive and HER2-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) in India.	Dr. Deepak Gupta
8.	Protocol Title: “Treatment patterns and clinical outcomes among Indian patients receiving Palbociclib combinations for HR+/HER2- Advanced/Metastatic breast cancer in real world settings.	Dr. Ajay Bapna
9.	A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of Imbruvica™ (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion (Ibrutinib)	Dr. Upendra Sharma
10.	Title & ID Ref: Rediux TM Registry to compare effectiveness safety, and Resource Utilization of Rediux TM vs the Reference Medicinal Product to Treat Diffuse Large B- Cell Lymphoma and Chronic Lymphocytic Leukaemia in Routine Clinical Practice (Phase-IV)	Dr. Upendra Sharma
11.	Ref No. “An open-label, multicenter, Phase IIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+)	Dr. Ajay Bapna



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

	HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease CLEE011A2404.	
12.	Protocol LEE011A2207 Ref: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Ajay Bapna
13.	CLDK378AIN01 A real-world, open-label, multi-center, prospective, non-interventional (observational) study to evaluate the effectiveness and tolerability of ceritinib in Indian patients with ALK positive metastatic non-small cell lung cancer who have progressed or are intolerant to crizotinib.	Dr. Pawan Agarwal
14.	Ref:A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1).	Dr. Aseem K Samar
15.	Protocol CA209-887: Safety Study of Nivolumab for Selected Advanced Malignancies in India	Dr. Aseem K Samar
16.	Protocol ALN-AT3SC-003: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX	Dr. Upendra Sharma
17.	Ref: ALN-AT3SC-004 A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX.	Dr. Upendra Sharma
18.	A Prospective, Randomized, Multicenter, Comparative, Open label, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC3256;Cadila Reference-Trastuzumab Emtansine (Kadcyla®, Roche Products (India) Pvt. Ltd.) in HER2- Positive Metastatic Breast Cancer Patients. (Breast Cancer)	Dr. Ajay Bapna
19.	Protocol No. : -“A randomised, double-blind, parallel group, equivalence, multicenter phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD204 to Avastin® in patients with metastatic or recurrent non-squamous non-small cell lung cancer” SAMSON-II (Lung Cancer)	Dr. L.M. Sharma
20.	CLDK378A2301 - A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer (Phase-III) (Alk Lung Cancer)	Dr. L.M. Sharma
21.	Study Title: Clinical Outcomes of CLL and MCL patients treated with Ibrutinib : An observational retrospective medical chart review from India	Dr. Naresh Somani
22.	Ref: Protocol: 0063-17_ A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Naresh Somani
23.	Reference: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer Protocol Number: DIV-SCLC-301	Dr. Naresh Somani
24.	<u>Reference:</u> Project # MYL-1402O-3001 :Multicentre, Double-Blind, Randomized,	Dr. Naresh



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

	Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First -line treatment of Patient with Stage IV Non-Squamous Non-Small Cell Lung Cancer. (Phase –III)	Somani
25.	Protocol Title:CPZP034AIC04 Parachute: Pazopanib Real-world Assessment of Clinical effectiveness and safety in patients who have Undergone treatment in different settings in advanced renal cell carcinoma; a prospective, non-interventional, observation study (Phase-IV)	Dr. Naresh Somani
26.	“Post-Mastectomy Radiation Therapy in High Risk, Node Negative women with Early Breast Cancer (PMRT-NNBC) “ (Investigator Initiative)	Dr. Nidhi Patni
27.	CT-P6 3.2- A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast Cancer (Phase – III)	Dr. Lalit Mohan Sharma
28.	Protocol No CT-P10 3.3- A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma.(Phase –III)	Dr. Lalit Mohan Sharma
29.	A Phase II, Multicenter, Randomized, open Label, and Parallel Group Study to Evaluate Safety and Efficacy of endoxifen as First- Line Therapy in Women with Metastatic Estrogen Receptor Positive Breast Cancer (Phase-II)	Dr. Pawan Agarwal
30.	Protocol CA209-887: Safety Study of Nivolumab for Selected Advanced Malignancies in India	Dr. Naresh Somani
31.	“A pilot study (Phase II Trial) of Nivolumab With Pemetrexed as Palliative Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations positive patients	Dr. Naresh Somani
32.	“A pilot study (Phase II Trial) of Gefitinib/Afatinib With Pemetrexed as First-Line Therapy in Patients With Advanced Non-squamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations positive patients.	Dr. Naresh Somani
33.	CBKM120H2201- Phase II multicenter randomized, double blind, placebo controlledstudy assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma.	Dr. Naresh Somani
34.	1200.131 LUX- Head & Neck 2: A randomized, double blind, placebo- controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.	Dr Naresh Somani
35.	IPI – 145- 21: A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma.	Dr Naresh Somani
36.	A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine,prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma	Dr. Naresh Somani
37.	An open label, Randomized, Parallel Group , Multi-centre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4	Dr. Naresh Somani



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

	Weeks in Pre-menopausal Women with Oestrogen Receptor positive Advanced Breast Cancer	
38.	Study Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer.	Dr. Naresh Somani
39.	Protocol: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Dr. Naresh Somani
40.	Protocol entitled “EPO-ANE-3010/Amendment INT-8 : A Randomized Open-Label, Multicentre, Phase 3 study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving First-Line Standard Chemotherapy”. Protocol No. EPO-ANE-3010	Dr. Naresh Somani
41.	Protocol No. 2-55-52030-730/TR321: Title” A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome	Dr. Naresh Somani
42.	“A Multi centre, open label, single arm, Phase IV, interventional study to evaluate the efficacy of Erlotinib (Tarceva®) following 4 cycles of platinum based chemotherapy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during Chemotherapy”	Dr. Naresh Somani
43.	Protocol I4T-MC-JVBA(c) (also known as IMCL CP12-1027[c]) A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	Dr. Naresh Somani
44.	Protocol WSA -CS-008: A Phase III, Double Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 versus a Caspofungin followed by Voriconazole Regimen in the Treatment of Candidemia and other Invasive Candida Infection”	Dr. Naresh Somani
45.	Protocol No. BI-1200.98, titled “An open label, phase II trial of BIBW 2992 (Afatinib) in patients with Metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant or adjuvant treatment setting”	Dr. Naresh Somani
46.	Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy	Dr. Naresh Somani
47.	An Open-Label, Multi-centre, Randomized, Active Controlled, Comparative, Phase III Clinical Study to Assess Efficacy and Safety of Lupin’s Filgrastim Versus Neupogen® as an Adjunct to Chemotherapy for Prevention of Neutropenia in Patients with Non-Myeloid Malignancies.	Dr. Naresh Somani
48.	An International, Multi- Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme	Dr. Naresh Somani
49.	A Phase III Randomized Placebo Controlled, Clinical Trial to Study the safety and Efficacy of V212 in Adult Patient with Solid Tumor or Hematologic Malignancy	Dr. Naresh Somani
50.	Protocol P1446-05/19/08: An Open Label, Multicenter Phase 1 Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies (Hence Referred To As ‘SERENITY’	Dr. Naresh Somani



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

51.	Protocol 276-00/31/08: An Open Label, Multicenter Phase/II Study Of Selective Cyclin Dependent Kinase Inhibitor P276-00 In Combination With Radiation In Subjects With Recurrent And/ Or Locally Advanced Squamous Cell Carcinoma Of Head And Neck.	Dr. Naresh Somani
52.	Axitinib (AG-013736) As Second Line Therapy For Metastatic Renal Cell Cancer : Axis Trial Protocol No. : A4061032	Dr. Naresh Somani
53.	Safety and Efficacy of Recombinant Human Granulocyte-colony Stimulating Factor-rhGCSF (ReliGrast TM or Neupogen®) in Patients with Chemotherapy Induced Neutropenia (Protocol No. : GMX-GCSF-CT001	Dr. Naresh Somani
54.	A Phase III, Randomized, Double –Blind Study of Galiximab in combination with Rituximab Compared with Rituximab in Combination with placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non- Hodgkin's Lymphoma. Study Number: 114-NH-301.	Dr. Naresh Somani
55.	A Multinational, Randomized, Double Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer. Protocol No. EFC – 10547	Dr. Naresh Somani
56.	A Multicentre Randomized, Double Blind, Placebo-Controlled, Parallel Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites, Protocol No. – EFC6125 (AVE0005A/3001)	Dr. Naresh Somani
57.	A Pivotal Phase 3 Observer-Blind Randomized Clinical Trial of the Efficacy and Safety of APF 530 Compared to Aloxi for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following Administration of Moderately or Highly Emetogenic Chemotherapy Regimens". Protocol No:C2006-01	Dr. Naresh Somani
58.	A Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma (Wyeth Study)	Dr. Naresh Somani
59.	A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (Folfiri) As Firstline Treatment. Protocol No. - A6181122	Dr. Naresh Soamni
60.	Phase III Randomized, Multi Center Study of Sunitinib Malate (SU 011248) or Capecitabine in Subjects with Advanced Breast Cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline therapy is not indicated. Study A6181107	Dr. Naresh Somani
61.	An Open-Label Sunitinib Malate (Su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment. Study A6181114	Dr. Naresh Somani
62.	A Two-Way Crossover Experimental Evaluation Of Relative Bioavailability Of Two Formulations Of Temozolomide 250 Mg Capsules In Adult Human Male And/Or Female Patients Under Fasting Conditions Protocol No. – 141-06	Dr. Naresh Somani
63.	International, Randomized,Open-label,phase 3 Trial of Paclitaxel / Carboplatin Plus PF-3512676 Versus Paclitaxel / Carboplatin Alone As First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer Protocol No. - A8501001	Dr. Naresh Somani
64.	A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer Protocol No. - H3E-MC-JMEN	Dr. Naresh Somani
65.	A Phase 2, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral	Dr. Naresh Somani



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

	Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer Protocol No. –SNX -1012- CLN2-006	
66.	A Multinational, Randomized, Double Blind Study, Comparing the Efficacy of Afibercept Once Every 2 weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer. Protocol No. EFC – 10547	Dr. Naresh Somani
67.	A Multicentre Randomized, Double Blind, Placebo-Controlled, Parallel Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites, Protocol No. – EFC6125 (AVE0005A/3001)	Dr. Naresh Somani
68.	A Pivotal Phase 3 Observer-Blind Randomized Clinical Trial of the Efficacy and Safety of APF 530 Compared to Aloxi for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following Administration of Moderately or Highly Emetogenic Chemotherapy Regimens”. Protocol No:C2006-01	Dr. Naresh Somani
69.	A Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma (Wyeth Study)	Dr. Naresh Somani
70.	A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (Folfiri) As Firstline Treatment. Protocol No. - A6181122	Dr. Naresh Soamni
71.	LUX-Lung 6: A randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with Stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation.	Dr. Naresh Somani
72.	Protocol No: B7391003“A Phase 3 Randomized, Double-Blind Study of Pf-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer.	Dr. Lalit Mohan Sharma
73.	Protocol No. L00070 IN 305 B0 : Study Title : A Phase III Study Of Vinflunine Pluse Capecitabine Versus Capecitabine Alone In Apatients With Advance Breast Cancer Previously Treated With Or Resistant To An Anthracycline And Who Are Taxane Resistant	Dr. Lalit Mohan Sharma
74.	AYUSH QOL-2C as an adjuvant therapy for patients of Cancer under chemotherapy/radiotherapy	Dr. Lalit Mohan Sharma
75.	FORTIS-M, LF-0207: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two of more prior treatment regimens	Dr. Lalit Mohan Sharma
76.	Protocol number: 1200.42 “Phase III randomized trial of Study drug plus weekly paclitaxel versus Investigator’s choice of chemotherapy following study drug monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment	Dr. Lalit Mohan Sharma
77.	Protocol MORAb-003-004: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse.	Dr. Lalit Mohan Sharma
78.	Phase II Clinical And Pharmacokinetic Trial of PM00104(Zalypsis ®)in Patients with Advanced and/ or Metastatic Endometrial or Cervical Cancer Previously Treated with One Line of Systemic Chemotherapy.	Dr. Lalit Mohan Sharma
79.	“A Phase IIb RCT of Neoadjuvant chemotherapy comparing Paclitaxel, ifosfamide and	Dr. Lalit



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

	Cisplatin with Paclitaxel, cisplatin and 5-FU in Patients with Locally Advanced Head and Neck Cancer."	Mohan Sharma
80.	A Prospective, Open Label Study of ANASTRZOLE In Post-Menopausal Women With Hormone Sensitive Advanced Breast Cancer Protocol No.-	Dr. Ajay Bapna
81.	A Randomized, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Fulvestrant (FASLODEXTM) 250 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing	Dr. Ajay Bapna
82.	A randomized, double blind, placebo controlled, Phase 2 study of oral recombinant human lactoferrin (rhLF) monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed 1 st or 2 nd line chemotherapy PNo. LF-0201	Dr. Ajay Bapna
83.	An Open label phase 2 study of oral recombinant human lactoferrin (rhLF) monotherapy in patients with advanced or metastatic renal cell carcinoma (RCC). Protocol No. LF-0202	Dr. Ajay Bapna
84.	A randomized, double blind, placebo controlled Phase 2 study of oral recombinant human lactoferrin (rhLF) in combination with Carboplatin and Paclitaxel (C/P) chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Protocol No. LF-0206	Dr. Ajay Bapna
85.	CPO44/06/FCNS: A Multicentre, Double blind, Double dummy Two phase crossover study of Nasalfent (Fentanyl Citrate Nasal Spray) compared to Immediate Release Morphine Sulphate Tablets in the treatment of Breakthrough Cancer Pain (BTCP) in subjects taking Regular Opioid Therapy.	Dr. Pushplata Gupta
86.	CP045/06/FCNS: An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy	Dr. Pushplata Gupta
87.	GWCA01103: A two-part, placebo- controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients with advanced cancer, who have inadequate analgesia even with optimized chronic opioid therapy.	Dr. Pushplata Gupta
88.	GWCA0999: A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain	Dr. Pushplata Gupta
89.	Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-029 /Neulasta® (Neulastim®) when given subcutaneously in patients with Chemotherapy Induced Neutropenia (Protocol No.: RLS/TP/2011/01; Version 5.0, Dated: 24 Mar 2014)	Dr. Pawan Agarwal
90.	BM100-CC-03-I-01 A Double Blind, Randomized, Active Controlled, Parallel Design, Comparative PK, Efficacy, Safety and Immunogenicity Study of Bmab-100 and Avastin®, both in Combination with XELOX Chemotherapy in Patients with Metastatic Colorectal Cancer	Dr. Pawan Agarwal